GRYPHON BIO

Therapeutic bioconjugates to accelerate CNS repair

OUR STORY

Gryphon Bio is a preclinical-stage therapeutic bioconjugate company created to harness our co-founders' discovery of unexpected waves of brain molecules in the blood, as novel therapeutic targets and temporal diagnostic (tDx) biomarkers, to accelerate central nervous system (CNS) repair.

​

We are developing a promising, diversified pipeline of lead therapeutic bioconjugates to accelerate CNS repair by following clues from nature’s sequence of cellular and molecular events. Each compound has a unique mechanism(s) of action (MOA) and pharmacokinetic/pharmacodynamic (PK/PD) profile, compelling biology, and binds to a novel or de-risked therapeutic target(s).

Mission: To develop and market the first therapeutic bioconjugate to accelerate CNS repair.

Vision: To pioneer therapeutic bioconjugates as safe and efficacious CNS medicines to improve the lives of patients.

OUR COURAGEOUS PATIENTS

CNS diseases are leading causes of death and disability, including:

• Traumatic brain injury (TBI)

• Multiple sclerosis (MS)

• Brain metastatic breast cancer (bmBC)

• Post-traumatic epilepsy (PTE)

• Alzheimer's disease (AD)

• Alzheimer's disease-related dementias (ADRD)

• Chronic traumatic encephalopathy (CTE)

• Frontotemporal degeneration (FTD)

• Spinal cord injury (SCI)

• COVID-19

​

WILL HASKINS, PHD

CEO & Co-Founder

Dr. Haskins, in collaboration with Drs. Wang and Forsthuber, discovered unexpected waves of brain molecules in the blood as temporal biomarkers and therapeutic targets. He previously led teams for R&D of gene therapies, therapeutic antibody and antibody-drug conjugates from Research through Phase I/II/III clinical trials for small and large biotechnology companies. Dr. Haskins is well-respected for developing and applying out-of-the-box solutions to challenging problems as a consultant for numerous biotechnology companies.

KEVIN WANG, PHD

Co-Founder & Chair of Scientific Advisory Board

Dr. Wang is an Associate Professor of Emergency Medicine and Neuroscience at the University of Florida, leading the Program for Neurotrauma, Neuroproteomics and Biomarker Research. He is an internationally-renowned leader for his discovery of temporal biomarker and therapeutic targets for traumatic brain injury with prominent roles in a number of national and international multi-institutional studies in traumatic brain injury and related neurological or neurodegenerative diseases. He was previously the Co-Founder and CSO of Banyan Biomarkers and President (current councilor) of the National Neurotrauma Society.

HENRY LOWMAN, PHD

Chief Technology Officer

Dr. Lowman has over 25 years of experience in drug discovery and development, with a focus on biologics. Following an NIH post-doctoral fellowship and scientist career at Genentech, he has held departmental leadership roles in antibody engineering at Genentech and NGM Biopharmaceuticals (NASDAQ: NGM), led the research team as CSO at CytomX Therapeutics (NASDAQ:CTMX), and served as Executive Vice President, Head of R&D at Triphase Accelerator US Corporation, a privately funded drug-development company.

FRANKLIN OKUMU, PHD

Technical and Regulatory Leader

Dr. Okumu is an experienced pharmaceutical development executive having previously led R&D teams from research through the development of multiple products and regulatory approvals for Genentech and Promius Pharma (Dr. Reddys Laboratories) including Kadcyla®, Perjeta®, Dificid®, Sernivo®, ZembraceSymtouch®, and Impoyz®. Dr. Okumu is the President and Chief Scientific Officer of EVO Pharmaceuticals Inc. and brings over 20 years of pharmaceutical product development experience to EVO.

ERIC BERNATH

Chief Operating Officer

Mr. Bernath was formerly a leader in global commercial operations, pricing, and market access at Amgen. Consequently, he is highly experienced with project management for successful drug development.

GET IN TOUCH

Gryphon Bio, Inc.
611 Gateway Blvd. Suite 120 #253
South San Francisco, CA 94080-7066